«In vivo study of targeted nanomedicine delivery into Langerhans cells by multiphoton laser scanning microscopy. «Kolonics A, Csiszovszzki Z, Toke ER, Lorincz O, Haluszka D, Szipocs R. Exp Dermatol. 2014 Aug;23(8):596-605.

«Vaccination of mice using the West Nile virus E-protein in a DNA prime-protein boost strategy stimulates cell-mediated immunity and protects mice against a lethal challenge. «De Filette M, Soehle S, Ulbert S, Richner J, Diamond MS, Sinigaglia A, Barzon L, Roels S, Lisziewicz J, Lorincz O, Sanders NN. Plos One. 2014 Feb 4;9(2):e87837.

«Safety, tolerability, and immunogenicity of repeated doses of dermavir, a candidate therapeutic HIV vaccine, in HIV-infected patients receiving combination antiretroviral therapy: results of the ACTG 5176 trial. «Rodriguez B, Asmuth DM, Matining RM, Spritzler J, Jacobson JM, Matlliard RB, li XD, Martinez AI, Tenoria AR, Lori F, Lisziewicz J, Yesmen S, Rinaldo CR, Pollard RB. J Acquired Immune Defic Syndr. 2013 Dec a;64(4):351-9.

«HIV vaccine to induce cytotoxic T cells recognizing conserved HIV-1/2-epitopes derived from the most frequent HLA types of the human population. «Somogyi E,  Lisziewicz J. Immunotherapy. 2013 Aug 5;5(8):825-8.

«DermAll nanomedicine for allergen-specific immunotherapy. «Garaczi E, Szaboo K, Francziszti L, Csiszovszki Z, Lorincz O, Toke ER, Molnar L, Bitai T, Janossy T, Bata-Csorgo Z, Kemeny L,  Lisziewicz J. Nanomedicine. 2013 Nov;9(8):1245-54.

«Nanomedicine applications towards the cure of HIV.» Lisziewicz J, Toke ER. Nanomedicine. 2013 Jan;9(1):28-38.

«Collision-induced dissociation study of poly(2-ethyl-2-oxazoline) using survival yields and breakdown curves.» Biri B, Nagy L, Kuki Á, Toke ER, Deák G, Zsuga M, Kéki S. J Mass Spectrom. 2013 Jan;48(1):16-23.

«HIV-specific immunotherapy with DermaVir, the first pDNA/PEIm pathogen-like nanomedicine.» Lisziewicz J., Lorincz O. European Journal of Nanomedicine Volume 4, Issue 2-4, Pages 81-87, DOI: 10.1515/ejnm-2012-0011

«Single DermaVir Immunization: Dose-Dependent Expansion of Precursor/Memory T Cells against All HIV Antigens in HIV-1 Infected Individuals» by Julianna Lisziewicz, Nyasha Bakare, Sandra A. Calarota, Dénes Bánhegyi, János Szlávik, Eszter Újhelyi, Eniko R. Toke, Levente Molnar, Zsolt Lisziewicz, Brigitte Autran, Franco Lori. PLoS ONE 7(5): e35416. doi:10.1371/journal.pone.0035416(2012)

«Structure and biological activity of pathogen-like synthetic nanomedicines» by Lorincz O., Toke E.R., Somogyi E., Horkay F., Chandran P.L., Douglas J.F., Szebeni J., Lisziewicz J. Nanomedicine: NBM 8 (2012) 497-506

«A plasmid DNA immunogen expressing fifteen protein antigens and complex virus-like particles (VLP(+)) mimicking naturally occurring HIV» by Somogyi E., Xu J., Gudics A., Tóth J., Kovács AL., Lori F., Lisziewicz J. Vaccine 29 (2011) 744–753

«Conference scene—active immunotherapeutics forum: meeting highlights» by Lisziewicz, J. Immunotherapy. 2009 Sep;1(5):743-8.

«Nanomedicine for dendritic cell-targeted immunotherapy» by Gudics, A., Lisziewicz, J. European Journal of Nanomedicine DOI 10.3884/0003.1.7; 2010.

«The Janus Face of Immune Stimulation by Nanomedicines:Examples for the Good and the Bad» by Lisziewicz, J., Szebeni, J. European Journal of Nanomedicine DOI 10.3884/0003.1.5; 2010.

«Rational development of a stable liquid formulation for nanomedicine products» by Toke, E., Lorincz, O., Somogyi, E., Lisziewicz, J. International Journal of Pharmaceutics 392:261-267, 2010.

«Unsung hero Robert C. Gallo«Abbadessa, G., Accolla, R., Aiuti, F., Albini, A., Aldovini, A., Alfano, M., Antonelli, G., Bartholomew, C., Bentwich, Z., Bertazzoni, U., Berzofsky, J.A., Biberfeld, P., Boeri, E., Buonaguro, L., Buonaguro, F.M., Bukrinsky, M., Burny, A., Caruso, A., Cassol, S., Chandra, P., Ceccherini-Nelli, L., Chieco-Bianchi, L., Clerici, M., Colombini-Hatch, S., de Giuli Morghen, C., de Maria, A., de Rossi, A., Dierich, M., Della-Favera, R., Dolei, A., Douek, D., Erfle, V., Felber, B., Fiorentini, S., Franchini, G., Gershoni, J.M., Gotch, F., Green, P., Greene, W.C., Hall, W., Haseltine, W., Jacobson, S., Kallings, L.O., Kalyanaraman, V.S., Katinger, H., Khalili, K., Klein, G., Klein, E., Klotman, M., Klotman, P., Kotler, M., Kurth, R., Lafeuillade, A., La Placa, M., Lewis, J., Lillo, F., Lisziewicz, J., Lomonico, A., Lopalco, L., Lori, F., Lusso, P., Macchi, B., Malim, M., Margolis, L., Markham, P.D., McClure, M., Miller, N., Mingari, M.C., Moretta, L., Noonan, D., O’Brien, S., Okamoto, T., Pal, R., Palese, P., Panet, A., Pantaleo, G., Pavlakis, G., Pistello, M., Plotkin, S., Poli, G., Pomerantz, R., Radaelli, A., Robertguroff, M., Roederer, M., Sarngadharan, M.G., Schols, D., Secchiero, P., Shearer, G., Siccardi, A., Stevenson, M., Svoboda, J., Tartaglia, J., Torelli, G., Tornesello, M.L., Tschachler, E., Vaccarezza, M., Vallbracht, A., van Lunzen, J., Varnier, O., Vicenzi, E., von Melchner, H., Witz, I., Zagury, D., Zagury, J.F., Zauli, G., and Zipeto, D. Science 323(5911):206-7, 2009.

«IL-15 as memory T-cell adjuvant for topical HIV-1 DermaVir vaccine» by Calarota, S.A., Dai, A., Trocio, J.N., Weiner, D.B., Lori, F., Lisziewicz, J. Vaccine. 26(40):5188-95, 2008.

«A Checkpoint in the Cell Cycle Progression as a Therapeutic Target to Inhibit HIV Replication/b>» by Foli, A., Maiocchi, M.A., Lisziewicz, J., and Lori, F. J Infect Dis. 196(9):1409-15, 2007.

«The potential of topical DNA vaccines adjuvanted by cytokines» by Lisziewicz, J., Calarota, S.A., and Lori F. Expert Opin Biol Ther. 7(10):1563-74, 2007.

«Nanochemistry-based immunotherapy for HIV-1.» by Lori, F., Calarota, S.A., and Lisziewicz, J.: Curr Med Chem. 14(18):1911-9, 2007.

«Induction of HIV-specific memory T-cell responses by topical DermaVir vaccine» by Calarota, S.A., Weiner, D.B., Lori, F., Lisziewicz, J. Vaccine 25(16):3070-4, 2007.

«Combining antiretroviral drugs and immune therapies: an approach to achieve clinical benefit after treatment interruption» by Julianna Lisziewicz. Current Opinion in HIV and AIDS Typeset by Thomson Digital for Lippincott Williams & Wilkins.

«HIV-1-Specific T Cell Precursors with High Proliferative Capacity Correlate with Low Viremia and High CD4 Counts in Untreated Individuals» by Sandra A. Calarota, Andrea Foli, Renato Maserati, Fausto Baldanti, Stefania Paolucci, Mary A. Young, Christos M. Tsoukas, Julianna Lisziewicz, and Franco Lori. The Journal of Immunology, February 27, 2008.

«HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3» by Anthony D. Cristillo, Julianna Lisziewicz, Leilei He, Franco Lori, Lindsey Galmin, Jeffrey N. Trocio, Tami Unangst, Lucia Whitman, Lauren Hudacik, Nyasha Bakare, Stephen Whitney, Susana Restrepo, John Suschak, Maria Grazi Ferrari, H.K. Chung, Vaniambadi S. Kalyanaraman, Phillip Markham, Ranajit Pal. Elsevier Science Direct, Virology 366 (2007) 197-211.

«DermaVir, a novel HIV immunisation technology» by Franco Lori!, Jeffrey Trocio, Nyasha Bakare, Laurene M. Kelly, Julianna Lisziewicz. Elsevier Vaccine 23 (2005) 2030–2034.

«Control of viral rebound through therapeutic immunization with DermaVir» by Julianna Lisziewicz, Jeffrey Trocio, Jianqing Xu, Lucia Whitman, Amy Ryder, Nyasha Bakare, Mark G. Lewis, Wendeline Wagner, Angela Pistorio, Suresh Arya, and Franco Lori. AIDS 2005, Vol 19 No 1.

«DermaVir: A Novel Topical Vaccine for HIV/AIDS» by Julianna Lisziewicz, Jeffrey Trocio, Lucia Whitman, Georg Varga, Jianqing Xu, Nyasha Bakare, Patrick Erbacher, Cecil Fox, Ruth Woodward, Phil Markham, Suresh Arya, Jean-Paul Behr, and Franco Lori. The Journal of Investigative Dermatology, 2004.

«Therapeutic vaccination for future management of HIV/AIDS» by Julianna Lisziewicz, Nyasha Bakare, Franco Lori. Elsevier Vaccine 21 (2003) 620–623.

«Induction of Potent Human Immunodeficiency Virus Type 1-Specific T-Cell-Restricted Immunity by Genetically Modified Dendritic Cells» by Julianna Lisziewicz, Dmitry I. Gabrilovich, Georg Varga, Jianqing Xu, Philip D. Greenberg, Suresh K. Arya, Marnix Bosch, Jean-Paul Behr, and Franco Lori. Journal of Virology, Aug. 2001, p. 7621–7628.

«Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection» by Franco Lori, Mark G. Lewis, Jianqing Xu, Georg Varga, Donald E. Zinn Jr., Carrol Crabbs, Wendeline Wagner, Jack Greenhouse, Peter Silvera, Jake Yalley-Ogunro, Carmine Tinelli, Julianna Lisziewicz. SCIENCE VOL 290 24 NOVEMBER 2000.

«Control of HIV despite the Discontinuation of Antiretroviral Therapy» by Julianna Lisziewicz, Eric Rosenberg, Judy Lieberman, Heiko Jessen, Lucia Lopalco, Robert Siliciano, Bruce Walker, and Franco Lori. The New England Journal of Medicine, Volume 340:1683 May 27, 1999 Number 21.


Semmelweis University (presentation and made an exam) — Development of theraputic vaccines – Budapest, Nov 25, 2011

4th European-Conference for Clinical Nanomedicine (CLINAM 2011) in collaboration with the European Technology Platform on Nanomedicine (ETPN), the European Medicines Agency (EMA) and the European Science Foundation (ESF): Nanomedicine for Development of Therapeutic Vaccines against Infectious Diseases, Immunological Disorders and Cancer – Basel, 23-25 May, 2011 (www.clinam.org)

Swiss NanoConvention 2011 — A conference on “How Nanotechnology will be shaping our Future”: Boosting the immune system with DermaVir nanomedicine: can it change the treatment paradigm of HIV? – Baden, 18-19 May, 2011 (www.swissnanoconvention.ch)

Innovation in Healthcare: from Research to Market (European Commission event): Entrepreneurship matters – the role of innovative SMEs — Bussels, March 30-31, 2011

Nanomedicine School: DermaVir Therapeutic HIV Vaccine: Synthetic Nanomedicine Formulation, Dendritic Cell-Targeted Topical Administration and Phase II Clinical Data — Buenos Aires, October 25-29, 2010

4th International Summer School on Nanosciences & Nanotechnologies (ISSON-10): pDNA nanomedicines for immunotherapy and vaccine – Halkidiki, 10-17 July, 2010

Annual ACTG meeting: confidential update on the German trial results – Washington DC, June 19, 2010

IMPAACT Group meeting: Clinical Studies with “DermaVir Therapeutic Vaccine”, a Dendritic Cell-Targeting Nanomedicine, Washington DC, June 9, 2010

«Fortbildung zum Thema «Nanopharmakologie» for 41 participants at Novartis Pharma AG, Switzerland: Clinical Development of Nanomedicines – Bern, November 4, 2009

Venture Contest — Partnering with the Immune System to Improve Human Health — Semi-Final: Eurecan European Venture Contest — Budapest, 28 October 2009

Seminar «Presentation about the Cluster, DermaVir, Technology«. Sacramento, CA, USA April 22. 2009

Enterprise Europe Network «Methods of Generating Projects in Clusters«. Budapest January 21, 2009

Pocok Klub «HIV/ADS Research«. Budapest November 29, 2008

VTC meeting «The New Medical Device, The New Nanomedicine Formulation, Dermavir Clinical and Regulatory Strategy«. Matrahaza, October 15-18, 2008

CROI 2008 «CROI: Single DermaVir Patch Treatment of HIV+ Individuals Induces Long-lasting, High-magnitude, and Broad HIV-specific T Cell Responses /poster«. Boston February 3-6 2008

VTC meeting «DermaVir Patch Development — update«. Matrahaza, October 24-27, 2007

15th International Congress of the Hungarian Society for Microbiology «DermaVir Patch vaccine for the treatment of HIV/AIDS«. Budapest July 18-20, 2007

SOTE Kôzegészségtan «DermaVir Pervention«. Budapest April 20, 2007

VTC meeting «HIV Vaccine Project«. Matrahaza, October 25-28, 2006

Aids Vaccine 2006 Conference «DermaVir patch therapeutic vaccine in chronic HIV infection: from the concept to the clinic». Amsterdam Aug 29-Sept 1, 2006

VTC Cluster Kick Off meeting «Overview of DermaVir Vaccine Technology«. Matrahaza, March 16-18, 2006

Immunomodulating drugs for the treatment of HIV/AIDS. «DermaVir Therapeutic Immunization for HIV-1 Infected Patients«. Lake Garda, Italy (2004.)

AIDS Vaccines 2005: «HIV-1 prophylactic vaccine comprised of topical DermaVir prime and protein boost elicits cellular immune responses and controls pathogenic R5 SHIV162P3» Montreal, Canada (2005.)

Immunologic Activation: Rational Design of Vaccines and Immunotherapeutics. «Therapeutic dendritic cell vaccination in chronic HIV infection«, Jean-Marie Andrieu, discussant Julianna Lisziewicz. Stockholm (2005.)

WCVI — Immunization — Great success of medicine. «DermaVir, a novel HIV immunization technology«. Tokyo, Japan (2004.)

Immune reconstitution and control of HIV. «Therapeutic Vaccines in Pre-Clinical Models«. Stresa, Lake Maggiore, Italy (2003.)

7th International Workshop on Langerhans cells. «DermaVir: A Langerhans Cell-mediated DNA Immunization Technology for the Induction of Cellular Immune Responses«. Stresa, Italy (2001.)

Vaccine Development and Immunotherapy «Therapeutic Vaccination: a Wide-impact Valuable Option«. San Juan, Puerto Rico (2001.)

9th Meeting of the European Society of Gene Therapy. «Genetic Immunization to control retrovirus replication in Macaques«. Antalya, Turkey (2001.)

Project Inform Workshop on Structured Treatment Interruptions. «Predictive Assays — VIR«. Chicago, Illinois (2000.)

Mater Medical Research Institute 2nd Annual Dendritic Cell Symposium. «Transcutaneous Genetic Modification of Lymph Node Dendritic Cells with Plasmid DNA«. Brisbane, Australia (2000.)


XIX. International AIDS Conference — Pre-Conference Symposium: “Towards an HIV Cure”: LB abstract- Postre presentation: Nanomedicine boosting broadly directed central memory T cells towards the eradication of HIV— Washington, July 22-27, 2012.

9th International Symposium on Polymer Therapeutics: From Laboratory to clinical Pratice: DermaVir HIV therapeutic Vaccine: Langerhans Cell-targeting delivery and clinical results — Valencia, Spain, May 28-30, 2012

5th European Conference for Clinical Nanomedicine (CLINAM): Langerhans Cell-targeting Immunotherapeutic Nanomedicine (DermaVir) Towards the Cure of HIV — Basel, May 7-9, 2012

World Vaccine Congress 2012: Introduction of Digital Personal Medicine (DPM) with DermaVir — Washington DC, April 10-13, 2012

3rd annual Active Immunotherapeutics Forum: Case study: DermaVir active immunotherapy for HIV: A technology for induction of Th1 type cellular immunity and clinical results — Barcelona, 11-13 May 2011

HIV DART 2010: DermaVir Therapeutic HIV Vaccine: Phase I and II Clinical Data in ARV Treated and Naďve HIV+ Subjects — Mexico, December 7-10, 2010

Gene-Based Vaccines 2010: DermaVir Therapeutic HIV Vaccine: A Topically Applied Synthetic Nanomedicine Formulation Targeting Dendritic Cells – Phase II Clinical Data – Cannes, November 8-10, 2010

2nd Annual ASNM conference: DermaVir therapeutic HIV vaccine: synthetic pDNA nanomedicine formulation, dendritic cell-targeted topical administration and phase II clinical data – Potomac, MD, October 14-16, 2010

MVAF Modern Vaccines/Adjuvants Formulation: DermaVir therapeutic HIV vaccine: synthetic pDNA nanomedicine formulation, dendritic cell-targeted topical administration and phase II clinical data – Cannes, October 13-15, 2010

Aids Vaccine 2010: Subtype-optimized DermaVir for personalized immunotherapy/poster (Eszter Somogyi) -Atlanta, September 28-October 1, 2010

11th International Symposium on Dendritic Cells in Fundamental and Clinical Immunology DC2010: Forum on Vaccine Science — Immunization with a nanomedicine targeting lymph nodes via dendritic cells -DermaVir therapeutic HIV vaccine candidate/poster – Lugano, September 26-30, 2010

International AIDS Conference: DermaVir for initial treatment of HIV infected subjects demonstrates preliminary safety, immunogenicity and HIV RNA reduction versus placebo immunization/poster — Nanotechnology to improve the biological activity of DNA vaccines/poster — Vienna, July 18-23, 2010

7th International Conference on Nanosciences & Nanotechnologies (NN10) — DermaVir pDNA/PEIm-based Immunotherapeutic nanomedicine for HIV/AIDS – Halkidiki, July 10-14, 2010

DNA Vaccines 2010 Conference — Structure and biological activity of synthetic DNA vaccines formulated to nanomedicines; DermaPrep, a Lymph Node Targeting Vaccine Administration Device / posters — New Orleans, March 2-4, 2010

Harnessing Immunity to Prevent and Treat Disease Conference: ANTIGENeering of plasmid DNA vaccines for personalized in vivo immunotherapy/poster (Eszter Somogyi) — Cold Spring Harbor, November 11-14, 2009

1st Annual Conference of the American Society for Nanomedicine (ASNM) — Plasmid DNA-based nanomedicines in the active immunotherapeutic field — Washington DC, October 22-25, 2009

Commercialization of Micro- and Nano Systems (COMS) 2009: Workshop Nanomedicine: pDNA/PEIm Immunotherapeutic Nanomedicine: from the discovery to the clinic — Copenhagen Aug 30- Sept 4. 2009.

Active Immunotherapeutics Forum 2009 «DermaVir: The next Geneation of DNA Vaccine». Barcelona June 22-24, 2009

BIO International Convention «Nanomedicines for Targeted Immune Amplification». Atlanta May 18-21,2009

2nd European Conference for Clinical Nanomedicine (CLINAM) «Hungarian network and country activity»,»How could Nanomedicine Resolve the Problem of HIV/AIDS», «HIV/AIDS: DermaVir Nanomedicine: the next Generation of DNA Vaccine in Clinical Phase II». Basel April 26-29, 2009

2nd Europe INNOVA Conference «Entrepreneurship matters: the role of innovative SMEs«. Lyon October 22-24, 2008

NanoDrugs 2008 «DermaVir«. London September 11-12, 2008

BIO International Convention «A Hugarian Strategy / Nanomedicine for the Global Market«. San Diego June 17-20 2008

Rodman & Renshaw 5th Annual Global Healthcare Conference «Clinical Development of ImmuneTherapy Platform with NanoComp and DermaPrep«. Monte Carlo May 19-20, 2008

Phacilitate Vaccine Forum Geneva 2008 «PANEL DISCUSSION: What is the path forward for the AIDS vaccine field?«. Geneva May 14-16, 2008

BioData Forum «Zsolt Lisziewicz / invited speaker«. Geneva January 22, 2008

Rodman & Renshaw 5th Annual Helathcare Conference «DermaVir Patch against HIV/AIDS«. New York November 5-7, 2007

Conf 1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity «1st INTERNATIONAL SYMPOSIUM on GENETIC and IMMUNE CORRELATES of HIV INFECTION and VACCINE-INDUCED IMMUNITY«. Budapest June 10-13, 2007

Rodman & Renshaw 4th Global Healthcare conference «DermaVir Patch against HIV/AIDS«. Monte Carlo May 14-15, 2007

HIV DART 2006 «Development of DermaVir Patch treament for HIV/AIDS» poster . Cancun December 10-16, 2006

12th Annual Congress in Immunology. «Non-APC Mediated HIV-1 Exogenous Antigen Presentation to CD8 T cells by uninfected CD4 T cells: a Novel Pathogenic Mechanism of HIV/AIDS can be corrected by Therapeutic Immunization«. Montreal, Canada (2004.)

11th conference on Retroviruses and Opportunistic Infections. «CD4-Dependent, non-APC Mediated Antigen Presentation Pathway: a Novel Pathogenetic Mechanism of Chronic HIV Infection Is Corrected by Therapeutic Vaccination«. San Francisco (2004.)

DNA Vaccines 2004 — The Gene Vaccine Conference. «DermaVir: a novel DNA based topically delivered vaccine«.Monte Carlo, Monaco (2004.)

HIV DART: Frontiers in drug development for antiretroviral therapies. «Impaired antigen presentation by CD4 T cells and its therapeutic implications«. Jamaica, West Indies (2004.)

AIDS Vaccine 2004. «Priming with DermaVir induces virus-specific cellular immune responses in uninfected rhesus macaques«. Lausanne, Switzerland (2004.)

XV International AIDS Conference. «Prophylactic DermaVir vaccination polarizes Th-1 type responses suppressing viral replication in Rhesus Macaques«. Bangkok, Thailand (2004.)

10th Conference on Retroviruses and Opportunistic Infections. «Specific, Efficient, and Short-lived DNA Expression in Lymph Node Dendritic Cells Mediates DermaVir’s Immunotherapeutic Effects«. Boston, USA (2003.)

2nd International Symposium on Molecular Diagnostics and Skin Gene Therapy. «Genetic modified dendritic cells to vaccinate against HIV«. Dusseldorf, Germany (2003.)

Sixth International Congress on Drug Therapy in HIV Infection. «DermaVir: A new topical DNA vaccine for the treatment of HIV/AIDS«. Glasgow, United Kingdom (2002.)

XIV Annual International AIDS Conference. «Safety, Immunogenicity and Antiviral Efficacy of a New Topical DNA Vaccine in Macaques with Chronic Infection and AIDS«. Barcelona, Spain (2002.)

9th Conference on Retroviruses and Opportunistic Infections. «Control of Viral Load Rebound during Treatment Interruptions in Macaques with AIDS Induced by a Novel Topical DNA Immunization (DermaVir)» and «A Novel Topical DNA Vaccine (DermaVir) for the Induction of T Cell Immunity«. Seattle, USA (2002.)

Third World Congress on Vaccines and Immunisation. «Novel dendritic cell-based topical DNA vaccination combined with STI-HAART induced immune control in macaques with AIDS«. Opatija, Croatia (2002.)

XIII Annual International AIDS Conference. «Novel HIV Vaccine for Induction of T Cell Immunity«. Durban, South Africa (2000.)